Project Grant F30CA294663
Award Date
12/17/24
Completion Date
6/30/26
Dollars Obligated
$216K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This $162,486 Project Grant, awarded by the National Cancer Institute (CFDA Program 93.398 - Cancer Research Manpower), supports research at Case Western Reserve University to study translation regulation and its role in glioblastoma (GBM) stem cell adaptation to hypoxic tumor environments. The research aims to use ribosome profiling and RNA sequencing to elucidate how translational regulation, rather than transcriptional regulation, enables GBM stem cells to survive and proliferate in...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $540,090 to The Regents of the University of California, San Francisco to conduct epigenetic analysis of osteosarcoma (a type of bone cancer) to define subtypes relevant to chemoresistance and metastasis. The overarching goal is to characterize the biological basis for these osteosarcoma subtypes and identify subtype-specific vulnerabilities that could lead to new targeted...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $514,405 to Sanford Research to investigate the role of cancer-dependent skeletal genes and pathways in the pathogenesis of osteosarcoma. The award will fund research to understand how cancer-dependent pathways involving p53 and Notch regulate premalignant osteoblasts and the development of osteosarcoma, a fatal bone tumor primarily affecting children. The project will utilize genetically...
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...
The federal Project Grant award, with ID F30CA294669, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $216,460 award to Case Western Reserve University (CWRU) aims to understand the mechanisms by which the EGFR L858R mutation affects tumor biology and provokes an anti-tumor immune response. The research will identify the L858R-derived neopeptides presented on HLA, examine the CD4+ and CD8+ T cell responses, and determine the...
This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $523,292 to the Dana-Farber Cancer Institute to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma. The project aims to assess the function of the MMEJ pathway in Ewing sarcoma tumor tissue and explore exploiting this unique DNA repair defect for therapeutic benefit. The award period...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to investigate the impacts of newly developed small molecule degraders that target the heat shock transcription factor 1 (HSF1) on acute myeloid leukemia (AML) stem cells. The $502,516 award to Case Western Reserve University, effective April 1, 2025 through March 31, 2030, will support research to determine the cellular effects of these HSF1 degraders on AML stem cell self-renewal, elucidate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...